JNJ ▼ -1.8% - Johnson & Johnson $JNJ - Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer 05-NOV-2026 09:04 PM ET